ReviewJournal of gastrointestinal cancer2014
Practical aspects of risk assessment in gastrointestinal stromal tumors.
Review in Journal of gastrointestinal cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Precision oncology meets Generative AI: assessing large language models in multidisciplinary GIST tumor boards.BMC cancer · 2026Article
- The Effectiveness and Safety of Endoscopic Intermuscular Dissection for the Treatment of Rectal Gastrointestinal Stromal Tumors: A Pilot Feasibility Study.Journal of clinical medicine · 2026Article
- Surgical treatment of gastrointestinal stromal tumors.Journal of medicine and life · 2026Review
- Pedunculated Extraluminal Gastrointestinal Stromal Tumor of Stomach: A Rare Case Report in South Korea.Case reports in surgery · 2026Article
- Article
- Differential Diagnosis and Molecular Stratification of Gastrointestinal Stromal Tumors on CT Images Using a Radiomics Approach.Journal of digital imaging · 2022Article
- Article
- Computed tomography-based radiomics model for discriminating the risk stratification of gastrointestinal stromal tumors.La Radiologia medica · 2020Article
- Retrospective Analysis of Chilean and Mexican GI Stromal Tumor Registries: A Tale of Two Latin American Realities.JCO global oncology · 2020Article
- Genetic Characterization of Molecular Targets in Korean Patients with Gastrointestinal Stromal Tumors.Journal of gastric cancer · 2020Article
- Combined endo-laparoscopic treatment of large gastrointestinal stromal tumor of the stomach: Report of a case and literature review.International journal of surgery case reports · 2020Article
- Retroperitoneal Extragastrointestinal Stromal Tumors Have a Poor Survival Outcome: A Multicenter Observational Study.Cancer management and research · 2020Article
- Enormous gastrointestinal stromal tumor arising from the stomach causing weight loss and anemia in an elderly female: Case report.International journal of surgery case reports · 2019Article
- Establishment and Verification of Prognostic Nomograms for Patients with Gastrointestinal Stromal Tumors: A SEER-Based Study.BioMed research international · 2019Article
- A cohort study of prognostic factors associated with recurrence or metastasis of gastrointestinal stromal tumor (GIST) of stomach.Annals of medicine and surgery (2012) · 2018Article
- Parallelism of DOG1 expression with recurrence risk in gastrointestinal stromal tumors bearing KIT or PDGFRA mutations.BMC cancer · 2016Article
- PDGFRA and KIT Mutation Status and Its Association With Clinicopathological Properties, Including DOG1.Oncology research · 2016Article
- Succinate dehydrogenase-deficient gastrointestinal stromal tumor of the stomach: EUS and contrast-enhanced EUS features (with videos).Endoscopic ultrasoundArticle
- Clinicopathological features, risk profile assessment, and the surgical outcome of gastrointestinal stromal tumors in Lagos, Nigeria.Annals of African medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionGastrointestinal stromal tumors (GISTs) are mesenchymal tumors of the gastrointestinal tract, which are characterized in the majority of cases by activating mutations in KIT and platelet-derived growth factor receptor alpha (PDGFRA). The introduction of tyrosine kinase inhibitors has revolutionized the management of patients with metastatic GIST. However, complete surgical resection remains the mainstay of management for those with localized disease. Recently, three large trials have confirmed the benefit of adjuvant imatinib therapy in patients who were at high risk of recurrence following complete resection. In this setting, it is critical that oncologists understand the various GIST risk assessment criteria and be able to apply these methods to accurately assess the risk of recurrence and the need for adjuvant imatinib therapy. PURPOSE: The aim of this review is to outline the risk stratification systems currently available to oncologists who are treating patients with GIST, so they can be optimally applied for clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.